Lurie Cancer Center Receives $4.27 Million from the Department of Defense for Breast Cancer Research

Publication
Article
OncologyONCOLOGY Vol 11 No 1
Volume 11
Issue 1

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Center of Northwestern University, announced that the Center has received a 4-year grant in the amount of $4.27 million from the US Army Medical Research and Materiel

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Centerof Northwestern University, announced that the Center has received a 4-yeargrant in the amount of $4.27 million from the US Army Medical Researchand Materiel Command for a project entitled, "Increasing Access toModern Multidisciplinary Breast Cancer Care."

The principal investigator of the project is Monica Morrow, MD, directorof the Lurie Cancer Center's Clinical Breast Cancer Research Program; associateprofessor, Department of Surgery, Northwestern University Medical School;and director of the Lynn Sage Comprehensive Breast Center at NorthwesternMemorial Hospital.

The award provides funds for eight research projects that focus on accessto breast cancer care by minority women; education of minority women andnonphysician providers who have contact with the medically underserved;dietary intervention to reduce cancer risk; methods to increase minorityparticipation in clinical trials; and the cost-effectiveness of new technologies.

The Robert H. Lurie Cancer Center of Northwestern University, a NationalCancer Institute-designated clinical cancer center, is the focus of cancerresearch, education, and patient care at Northwestern University. The LurieCancer Center coordinates clinical research and cancer patient care programsat the teaching affiliates of the Northwestern University Medical Schooland, through the Northwestern Healthcare Network, is associated with thecancer programs at nine hospitals in the Chicago area.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content